相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients
N. Janus et al.
ANNALS OF ONCOLOGY (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743)
Jan Handrick Beumer et al.
CURRENT CLINICAL PHARMACOLOGY (2009)
Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis
Juliette Thariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
Jan H. Beumer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis (R)) in cancer patients
Juan Jose Perez-Ruixo et al.
CLINICAL PHARMACOKINETICS (2007)
Hepatotoxicity and metabolism of trabectedin: a literature review
JH Beumer et al.
PHARMACOLOGICAL RESEARCH (2005)
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
TA Puchalski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man
RW Sparidans et al.
ANTI-CANCER DRUGS (2001)
分享论文
